Latest filing published 24 Sept 2026 for Theravance Biopharma, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Aine Miller discloses dealings in Theravance Biopharma, Inc. to SEC (Form 4). We count 14 filings; the first trade dates from 20 February 2024 and the latest from 23 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 24 September 2026, the filings show a transaction in Theravance Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations